Laboratory assessment of liver function in people starting antiretroviral therapy with Dolutegravir or Efavirenz: a cohort study in Belo Horizonte, Brazil

Detalhes bibliográficos
Autor(a) principal: Cesar, Jorgino Julio
Data de Publicação: 2022
Outros Autores: Silveira, Micheline Rosa, Maia, Paulo Roberto, Souza, Cléssius Ribeiro de, Penido, Henrique Pereira de Aguilar, Fernandes, Ana Cristina da Silva, Ceccato, Maria das Graças Braga
Tipo de documento: Artigo
Idioma: por
Título da fonte: Research, Society and Development
Texto Completo: https://rsdjournal.org/index.php/rsd/article/view/35082
Resumo: Objective: to verify which antiretroviral treatment regimen was safer for people living with HIV, dolutegravir 50mg + lamivudine 300mg + tenofovir 300mg or efavirenz 600mg + lamivudine 300mg + tenofovir 300mg. For this, the following laboratory tests of liver function were analyzed: total, direct and indirect bilirubin, aspartate amino transferase, alanine amino transferase, gamma glutamyl transferase and alkaline phosphatase. Methodology: cohort study, with the follow-up of 234 people living with HIV and starting antiretroviral therapy in the city of Belo Horizonte, Minas Gerais, Brazil, with data collected between August 2015 and December 2018. Results: Mean values for the results of total and indirect bilirubin, aspartate amino transferase, alanine amino transferase and alkaline phosphatase tests reduced after 72 weeks for the two therapeutic regimens. The mean value for direct bilirubin in people taking efavirenz increased at 72 weeks and was above baseline compared to baseline. For gamma glutamyl transferase, the mean of the results was above the reference value in both groups before treatment. After 72 weeks of therapy with dolutegravir, the mean returned to baseline and, in the case of efavirenz, the mean remained high. Bonett's and Dunnett's tests had no statistical difference, indicating that the two therapeutic regimens are safe. Conclusions: the two therapeutic regimens studied proved to be safe and did not cause an increase in the variance for laboratory tests that were markers of liver function.
id UNIFEI_a7e6ecc89925d9afd8f4ddf648d0aa3f
oai_identifier_str oai:ojs.pkp.sfu.ca:article/35082
network_acronym_str UNIFEI
network_name_str Research, Society and Development
repository_id_str
spelling Laboratory assessment of liver function in people starting antiretroviral therapy with Dolutegravir or Efavirenz: a cohort study in Belo Horizonte, BrazilEvaluación de laboratorio de la función hepática en personas que inician terapia antirretroviral con Dolutegravir o Efavirenz: un estudio de cohorte en Belo Horizonte, Brasil Avaliação laboratorial da função hepática em pessoas iniciando a terapia antirretroviral com esquemas contendo Dolutegravir ou Efavirenz: estudo de coorte em Belo Horizonte, BrasilHighly Active Antiretroviral TherapyLiver CellsDrug response biomarkers.Terapia Antirretroviral de Gran ActividadCelulas hepáticasBiomarcadores de respuesta a fármacos.Terapia Antirretroviral de Alta AtividadeCélulas HepáticasBiomarcadores de resposta a medicamentos. Objective: to verify which antiretroviral treatment regimen was safer for people living with HIV, dolutegravir 50mg + lamivudine 300mg + tenofovir 300mg or efavirenz 600mg + lamivudine 300mg + tenofovir 300mg. For this, the following laboratory tests of liver function were analyzed: total, direct and indirect bilirubin, aspartate amino transferase, alanine amino transferase, gamma glutamyl transferase and alkaline phosphatase. Methodology: cohort study, with the follow-up of 234 people living with HIV and starting antiretroviral therapy in the city of Belo Horizonte, Minas Gerais, Brazil, with data collected between August 2015 and December 2018. Results: Mean values for the results of total and indirect bilirubin, aspartate amino transferase, alanine amino transferase and alkaline phosphatase tests reduced after 72 weeks for the two therapeutic regimens. The mean value for direct bilirubin in people taking efavirenz increased at 72 weeks and was above baseline compared to baseline. For gamma glutamyl transferase, the mean of the results was above the reference value in both groups before treatment. After 72 weeks of therapy with dolutegravir, the mean returned to baseline and, in the case of efavirenz, the mean remained high. Bonett's and Dunnett's tests had no statistical difference, indicating that the two therapeutic regimens are safe. Conclusions: the two therapeutic regimens studied proved to be safe and did not cause an increase in the variance for laboratory tests that were markers of liver function.Objetivo: verificar qué régimen de tratamiento antirretroviral fue más seguro para las personas que viven con el VIH, dolutegravir 50 mg + lamivudina 300 mg + tenofovir 300 mg o efavirenz 600 mg + lamivudina 300 mg + tenofovir 300 mg. Para ello se analizaron las siguientes pruebas de laboratorio de función hepática: bilirrubina total, directa e indirecta, aspartato amino transferasa, alanina amino transferasa, gamma glutamil transferasa y fosfatasa alcalina. Metodología: estudio de cohorte, con seguimiento de 234 personas viviendo con VIH e iniciando terapia antirretroviral en la ciudad de Belo Horizonte, Minas Gerais, Brasil, con datos recolectados entre agosto de 2015 y diciembre de 2018. Resultados: Valores medios para el los resultados de las pruebas de bilirrubina total e indirecta, aspartato amino transferasa, alanina amino transferasa y fosfatasa alcalina se redujeron después de 72 semanas para los dos regímenes terapéuticos. El valor medio de bilirrubina directa en personas que tomaban efavirenz aumentó a las 72 semanas y estuvo por encima del valor inicial en comparación con el valor inicial. Para gamma glutamil transferasa, la media de los resultados estaba por encima del valor de referencia en ambos grupos antes del tratamiento. Después de 72 semanas de tratamiento con dolutegravir, la media volvió al valor inicial y, en el caso de efavirenz, la media permaneció alta. Las pruebas de Bonett y Dunnett no tuvieron diferencia estadística, lo que indica que los dos regímenes terapéuticos son seguros. Conclusiones: los dos regímenes terapéuticos estudiados demostraron ser seguros y no provocaron un aumento en la varianza para los exámenes de laboratorio que fueron marcadores de la función hepática.Objetivo: verificar qual esquema de tratamento antirretroviral foi mais seguro para pessoa que vive com HIV, dolutegravir 50mg + lamivudina 300mg + tenofovir 300mg ou efavirenz 600mg + lamivudina 300mg + tenofovir 300mg. Para isso, analisou-se os seguintes exames laboratoriais de função hepática: bilirrubina total, direta e indireta, aspartato amino transferase, alanina amino transferase, gama glutamil transferase e fosfatase alcalina. Metodologia: estudo de coorte, com o acompanhamento de 234 pessoas que vivem com HIV e iniciando terapia antirretroviral na cidade de Belo Horizonte, Minas Gerais, Brasil, com dados coletados entre agosto de 2015 a dezembro de 2018. Resultados: Os valores médios para os resultados dos exames bilirrubina total e indireta, aspartato amino transferase, alanina amino transferase e fosfatase alcalina reduziram após 72 semanas para os dois esquemas terapêuticos. A média do valor para a bilirrubina direta nas pessoas em uso de efavirenz aumentou em 72 semanas e ficou acima do valor de referência, quando comparado com a do início do acompanhamento. Para a gama glutamil transferase, a média dos resultados apresentou-se acima do valor de referência em ambos os grupos antes do tratamento. Após a terapia por 72 semanas com dolutegravir, a média retornou ao valor de referência e, no caso do efavirenz, a média manteve-se elevada. Os testes de Bonett e de Dunnett não tiveram diferença estatística, indicando que os dois esquemas terapêuticos são seguros. Conclusões: os dois esquemas terapêuticos estudados mostraram-se seguros e não ocasionaram aumento na variância para exames laboratoriais marcadores de função hepática.Research, Society and Development2022-09-28info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/3508210.33448/rsd-v11i13.35082Research, Society and Development; Vol. 11 No. 13; e74111335082Research, Society and Development; Vol. 11 Núm. 13; e74111335082Research, Society and Development; v. 11 n. 13; e741113350822525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/35082/29488Copyright (c) 2022 Jorgino Julio Cesar; Micheline Rosa Silveira; Paulo Roberto Maia; Cléssius Ribeiro de Souza; Henrique Pereira de Aguilar Penido; Ana Cristina da Silva Fernandes; Maria das Graças Braga Ceccatohttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessCesar, Jorgino Julio Silveira, Micheline RosaMaia, Paulo Roberto Souza, Cléssius Ribeiro de Penido, Henrique Pereira de Aguilar Fernandes, Ana Cristina da Silva Ceccato, Maria das Graças Braga2022-10-17T13:43:46Zoai:ojs.pkp.sfu.ca:article/35082Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:50:07.750437Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false
dc.title.none.fl_str_mv Laboratory assessment of liver function in people starting antiretroviral therapy with Dolutegravir or Efavirenz: a cohort study in Belo Horizonte, Brazil
Evaluación de laboratorio de la función hepática en personas que inician terapia antirretroviral con Dolutegravir o Efavirenz: un estudio de cohorte en Belo Horizonte, Brasil
Avaliação laboratorial da função hepática em pessoas iniciando a terapia antirretroviral com esquemas contendo Dolutegravir ou Efavirenz: estudo de coorte em Belo Horizonte, Brasil
title Laboratory assessment of liver function in people starting antiretroviral therapy with Dolutegravir or Efavirenz: a cohort study in Belo Horizonte, Brazil
spellingShingle Laboratory assessment of liver function in people starting antiretroviral therapy with Dolutegravir or Efavirenz: a cohort study in Belo Horizonte, Brazil
Cesar, Jorgino Julio
Highly Active Antiretroviral Therapy
Liver Cells
Drug response biomarkers.
Terapia Antirretroviral de Gran Actividad
Celulas hepáticas
Biomarcadores de respuesta a fármacos.
Terapia Antirretroviral de Alta Atividade
Células Hepáticas
Biomarcadores de resposta a medicamentos.
title_short Laboratory assessment of liver function in people starting antiretroviral therapy with Dolutegravir or Efavirenz: a cohort study in Belo Horizonte, Brazil
title_full Laboratory assessment of liver function in people starting antiretroviral therapy with Dolutegravir or Efavirenz: a cohort study in Belo Horizonte, Brazil
title_fullStr Laboratory assessment of liver function in people starting antiretroviral therapy with Dolutegravir or Efavirenz: a cohort study in Belo Horizonte, Brazil
title_full_unstemmed Laboratory assessment of liver function in people starting antiretroviral therapy with Dolutegravir or Efavirenz: a cohort study in Belo Horizonte, Brazil
title_sort Laboratory assessment of liver function in people starting antiretroviral therapy with Dolutegravir or Efavirenz: a cohort study in Belo Horizonte, Brazil
author Cesar, Jorgino Julio
author_facet Cesar, Jorgino Julio
Silveira, Micheline Rosa
Maia, Paulo Roberto
Souza, Cléssius Ribeiro de
Penido, Henrique Pereira de Aguilar
Fernandes, Ana Cristina da Silva
Ceccato, Maria das Graças Braga
author_role author
author2 Silveira, Micheline Rosa
Maia, Paulo Roberto
Souza, Cléssius Ribeiro de
Penido, Henrique Pereira de Aguilar
Fernandes, Ana Cristina da Silva
Ceccato, Maria das Graças Braga
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Cesar, Jorgino Julio
Silveira, Micheline Rosa
Maia, Paulo Roberto
Souza, Cléssius Ribeiro de
Penido, Henrique Pereira de Aguilar
Fernandes, Ana Cristina da Silva
Ceccato, Maria das Graças Braga
dc.subject.por.fl_str_mv Highly Active Antiretroviral Therapy
Liver Cells
Drug response biomarkers.
Terapia Antirretroviral de Gran Actividad
Celulas hepáticas
Biomarcadores de respuesta a fármacos.
Terapia Antirretroviral de Alta Atividade
Células Hepáticas
Biomarcadores de resposta a medicamentos.
topic Highly Active Antiretroviral Therapy
Liver Cells
Drug response biomarkers.
Terapia Antirretroviral de Gran Actividad
Celulas hepáticas
Biomarcadores de respuesta a fármacos.
Terapia Antirretroviral de Alta Atividade
Células Hepáticas
Biomarcadores de resposta a medicamentos.
description Objective: to verify which antiretroviral treatment regimen was safer for people living with HIV, dolutegravir 50mg + lamivudine 300mg + tenofovir 300mg or efavirenz 600mg + lamivudine 300mg + tenofovir 300mg. For this, the following laboratory tests of liver function were analyzed: total, direct and indirect bilirubin, aspartate amino transferase, alanine amino transferase, gamma glutamyl transferase and alkaline phosphatase. Methodology: cohort study, with the follow-up of 234 people living with HIV and starting antiretroviral therapy in the city of Belo Horizonte, Minas Gerais, Brazil, with data collected between August 2015 and December 2018. Results: Mean values for the results of total and indirect bilirubin, aspartate amino transferase, alanine amino transferase and alkaline phosphatase tests reduced after 72 weeks for the two therapeutic regimens. The mean value for direct bilirubin in people taking efavirenz increased at 72 weeks and was above baseline compared to baseline. For gamma glutamyl transferase, the mean of the results was above the reference value in both groups before treatment. After 72 weeks of therapy with dolutegravir, the mean returned to baseline and, in the case of efavirenz, the mean remained high. Bonett's and Dunnett's tests had no statistical difference, indicating that the two therapeutic regimens are safe. Conclusions: the two therapeutic regimens studied proved to be safe and did not cause an increase in the variance for laboratory tests that were markers of liver function.
publishDate 2022
dc.date.none.fl_str_mv 2022-09-28
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/35082
10.33448/rsd-v11i13.35082
url https://rsdjournal.org/index.php/rsd/article/view/35082
identifier_str_mv 10.33448/rsd-v11i13.35082
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/35082/29488
dc.rights.driver.fl_str_mv https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Research, Society and Development
publisher.none.fl_str_mv Research, Society and Development
dc.source.none.fl_str_mv Research, Society and Development; Vol. 11 No. 13; e74111335082
Research, Society and Development; Vol. 11 Núm. 13; e74111335082
Research, Society and Development; v. 11 n. 13; e74111335082
2525-3409
reponame:Research, Society and Development
instname:Universidade Federal de Itajubá (UNIFEI)
instacron:UNIFEI
instname_str Universidade Federal de Itajubá (UNIFEI)
instacron_str UNIFEI
institution UNIFEI
reponame_str Research, Society and Development
collection Research, Society and Development
repository.name.fl_str_mv Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)
repository.mail.fl_str_mv rsd.articles@gmail.com
_version_ 1797052724345307136

Registros relacionados